Cartesian Therapeutics Inc. 2026年季度报告

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _______ to _______Commission File Number: 001-37798 Cartesian Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (301) 348-8698 (Registrant’s telephone number,including area code) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐NoAs of April23, 2026, the registrant had 29,381,514 shares of common stock, par value $0.0001 per share, outstanding. PART I. FINANCIAL INFORMATION Item 1.Financial Statements (unaudited)Consolidated Balance Sheets as of March 31, 2026and December 31, 2025Consolidated Statements of Operations and Comprehensive Loss for the Three Months ended March 31, 2026and 2025 PART II. OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or the Quarterly Report, contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section27A of theSecurities Act of 1933, as amended, or the Securities Act, and Section21E of the Securities Exchange Act of 1934, as amended, or theExchange Act. All statements other than statements of historical facts contained in this Quarterly Report, including statementsregarding our future results of operations and financial position, business strategy, prospective products, product approvals, researchand development costs, timing and likelihood of success, the plans and objectives of management for future operations and futureresults of anticipated products, the impact of future pandemics or similar events on our business and operations and our future In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,”“anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”, or “continue” or thenegative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report are only predictions. Wehave based these forward-looking statements largely on our current expectations and projections about future events and financialtrends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak •our future results of operations and financial position, business strategy, and the length of time that we believe our existingcash resources will fund our operations; •our market size and our potential growth opportunities; •our preclinical and clinical development activities; •our dependence on third-parties, including contract research organizations in the conduct of our pre-clinical studies andclinical trials; •the efficacy and safety profile of our product candidates; •the potential therapeutic benefits and economic value of our product candidates; •the timing and results of preclinical studies and clinical trials; •the potential impairment of our goodwill and indefinite lived intangible assets; •the expected impact of macroeconomic conditions, including inflation, increasing interest rates, volatile market conditionsand current or potential bank failures; •the impact of global events, including the ongoing conflicts between Russia and Ukraine, the ongoing conflict in the MiddleEast and geopolitical tensions with China; •the impact of political uncertainty on our product development; •the receipt and timing of potential regu